All Articles
Test availability at launch can be underestimated, under-budgeted and under-resourced: an example using real-time, real world analysis of PD-L1

Test availability at launch can be underestimated, under-budgeted and under-resourced: an example using real-time, real world analysis of PD-L1

25 May, 2017

Diaceutics gave a presentation at TriCON 2017 discussing how biomarkers and diagnostics are still falling short at launch, even though the industry is no longer in its infancy. Here, Jordan Clark, Managing Director, reports on how we can track the real-time, real-world development of PD-L1 in NSCLC and highlights the differences in the test's availability, budgeting and resourcing.

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.